SOURCE: Ablynx

March 25, 2010 13:25 ET

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

GHENT, BELGIUM--(Marketwire - March 25, 2010) -


REGULATED INFORMATION

Ablynx [Euronext Brussels: ABLX], the biopharmaceutical company focused on the discovery and development of Nanobodies(®), announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), it received the following notifications of holdings between 22 March 2010 and 25 March 2010.

+----------------------------+-----------------------+-------------------------+
|Notifying person(s)         |Number of voting rights|Percentage of voting     |
|                            |                       |rights                   |
+----------------------------+-----------------------+-------------------------+
|Gimv  NV,  Adviesbeheer Gimv|       7,991,430       |         18.33%          |
|Life       Sciences      NV,|                       |                         |
|Adviesbeheer    Gimv    Life|                       |                         |
|Sciences 2004 NV and Biotech|                       |                         |
|Fonds Vlaanderen NV(1)      |                       |                         |
+----------------------------+-----------------------+-------------------------+
|C.H.  Boehringer  Sohn  AG &|       2,142,857       |          4.92%          |
|Co.    KG   and   Boehringer|                       |                         |
|Ingelheim International GmbH|                       |                         |
|(2)                         |                       |                         |
+----------------------------+-----------------------+-------------------------+
|Multifund  B.V., Nederlandia|       1,900,000       |          4.36%          |
|Investments     B.V.     and|                       |                         |
|Stichting Avivia(3)         |                       |                         |
+----------------------------+-----------------------+-------------------------+
|KBC  Group  and  KBC Private|       1,264,822       |          2.90%          |
|Equity(4)                   |                       |                         |
+----------------------------+-----------------------+-------------------------+

(1)Gimv NV controls Adviesbeheer Gimv Life Sciences NV and Adviesbeheer Gimv Life Sciences 2004 NV. Gimv NV (3,374,626 voting rights), Adviesbeheer Gimv Life Sciences NV (555,523 voting rights), Adviesbeheer Gimv Life Sciences 2004 NV (40,000 voting rights), and Biotech Fonds Vlaanderen NV (4,021,281voting rights) are acting in concert. The Flemish Region is the ultimate shareholder of Biotech Fonds Vlaanderen NV.

(2 )C.H. Boehringer Sohn AG & Co. KG (0 voting rights) is the parent undertaking controlling Boehringer Ingelheim International GmbH (2,142,857 voting rights).

(3) Multifund B.V. (570,000 voting rights) is entrusted with the management and the exercise of the voting rights. Stichting Avivia controls Nederlandia Investments B.V. (1,330,000 voting rights).

(4)KBC Group NV (0 voting rights) is the parent company, of which KBC Bank NV (0 voting rights) is a direct subsidiary. KBC Private Equity NV (1,264,822 voting rights) is a direct subsidiary of KBC Bank NV.

The total number of voting securities (denominator) and the total number of voting rights of Ablynx amount to 43,590,173.

Full versions of all transparency notifications are available on the website of Ablynx (www.ablynx.com - investor relations).

-ends-

For more information, please contact Ablynx:

Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com 

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com

Wim Ottevaere
Chief Financial Officer
t: +32 (0)9 262 00 08
e: wim.ottevaere@ablynx.com 



[HUG#1397884]





Complete version of the press release: http://hugin.info/137912/R/1397884/353639.pdf



Contact Information